RxDoctor Payments Data

Eunae Ko

Primary Care · New York, NYNPI 1003272865

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Viiv Healthcare Company at 42.7% of the total. Reporting peaked in 2023 at $1,213 and has fallen 83.5% since, to $200 in 2025. Among primary care clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,795in general payments, 2019–2025

Across 159 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$665
  • Johnson & Johnson$355
  • Theratechnologies Inc.$316
  • Janssen Products, LP$224
  • EMD Serono, Inc.$205
  • plus $409 from 9 others

What the payments were for

  • Food & beverage$3,69697%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,795 in reported general payments places this provider in the 90th percentile of 239 primary care providers in New York.

See all primary care providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine32$88,883
BiktarvyBictegrav/Emtricit/Tenofov Ala16$68,071
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)15$7,748
Fluticasone Propionate12$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato$1,621$88,88332 claims
GileadBiktarvy$665$68,07116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 239 primary care providers in New York.

Other primary care in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →